0 antall prosjekter

GLOBVAC-Global helse- og vaksin.forskn

Towards a functional Cure for HIV: Combining reservoir purging agent (HDACi) with therapeutic vaccination (Vacc-4x)- The REDUC Study.

Infeksjon med humant immunsvikt virus (HIV)-1 truer fortsatt den globale helsen. I 2015 var det 36.7 millioner mennesker som levde med HIV-1 på verdensbasis. HIV-infeksjon behandles med en kombinasjon av antiretrovirale midler (ART) som kan redusere virusmengden i blodet til under deteksjonsnivå....

Tildelt: kr 16,6 mill.

Prosjektperiode: 2014-2017

Sted: Oslo

GLOBVAC-Global helse- og vaksin.forskn

Vacc-HIV: A novel therapeutic vaccine combination for HIV infection

Livslang kombinert antiretroviral behandling (ART) representerer gullstandarden for behandling av humant immunsvikt virus (HIV) infeksjon. Siden 2013 har retningslinjene for HIV behandling anbefalt at ART medisin gis til alle som lever med HIV uansett deres CD4 tall (immunstatus). I 2012 fikk 9.7...

Tildelt: kr 6,3 mill.

Prosjektperiode: 2013-2016

Sted: Oslo

GLOBVAC-Global helse- og vaksin.forskn

Towards Eradication of HIV-1: Therapeutic Vaccination with the peptide-based candidate Vacc-4x

Vacc-4x Reboost studien (NCT01712256) var en videreføring av den store fase II kliniske studien (NCT00659789) der den peptid-baserte terapeutiske HIV vaksinekandidaten, Vacc-4x, induserte en statistisk signifikant reduksjon i virusmengde (set-point) sammenlignet med placebo etter at antiretrovira...

Tildelt: kr 6,4 mill.

Prosjektperiode: 2012-2018

Sted: Oslo

GLOBHELS-Global helse

Studies to complete the phase II clinical stage of development for the peptide-based HIV-1 therapeutic vaccine candidate Vacc-4x.

Combination antiretroviral therapy (ART) for HIV infection has improved the longevity of infected individuals and as new infections occur each year, the overall number in need of ART is rising increasing the financial burden for healthcare services. ART l imitations include increasing multidrug r...

Tildelt: kr 7,5 mill.

Prosjektperiode: 2009-2012

Sted: Oslo

BIA-Brukerstyrt innovasjonsarena

Development of a peptide-based therapeutic vaccine to combat HIV disease (chronic immune stimulation)

This project aims to develop a novel therapeutic vaccine that induces nonneutralising antibodies to human immunodeficiency virus (HIV) to modulate disease rather than inhibit infection. Much evidence has now accumulated supporting the concept that acquire d immunodeficiency syndrome (AIDS) is an ...

Tildelt: kr 11,3 mill.

Prosjektperiode: 2008-2011

Sted: Oslo

GLOBHELS-Global helse

Phase IIb-Test of Concept Clinical Trial of the Peptide-based HIV-1 Therapeutic Vaccine Candidate Vacc-4x

Combination antiretroviral therapy (ART), the daily life long treatment for human immunodeficiency virus (HIV) infection is costly and associated with adverse side effects following long term use (e.g. metabolic toxicity). This study will further the cli nical development of the peptide-based HI...

Tildelt: kr 5,0 mill.

Prosjektperiode: 2008-2009

Sted: Oslo

FUGE-Funksjonell genomforskn.i Norg

Development of a Peptide-based Universal Influenza Vaccine

This study aims to develop a safe and effective peptide-based universal influenza vaccine targeting dendritic cells, that stimulates cell mediated immunity to reduce morbidity and mortality associated with influenza virus infection. Such a vaccine can be made in advance of a pandemic and can also...

Tildelt: kr 8,2 mill.

Prosjektperiode: 2006-2010

Sted: Oslo

BIA-Brukerstyrt innovasjonsarena

Advances in peptide design and laboratory testing to identify suitable peptide-based HIV immunotherapy candidates for product development

The objective of this project is to analyse and select a range of immunogenic peptides as candidate HIV immunotherapies for future human clinical trials. Immunotherapy strategies are needed to counteract both the financial and physical burdens of current HIV drugs on human health. Drug-resistant ...

Tildelt: kr 5,8 mill.

Prosjektperiode: 2006-2008

Sted: Oslo

PES-EU-Prosjektetablererstøtte EU (bedrift)

Prosjektetablering i forbindelse med EU-søknad ang. ny peptidbasert immunterapi for HIV-smittede

...

Tildelt: kr 50 999

Prosjektperiode: 2004-2004

Sted: Oslo